EUVIMEDEUVIMED entdecken
Multizentrische Studie

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma

Michael Sargent Binkley iD, Jamie E Flerlage iD, Kerry J Savage iD, Saad Akhtar, Raphael Steiner iD, Xiao-Yin Zhang, Michael Dickinson iD, Anca Prica, Ajay Major iD, Peter G Hendrickson, David Hopkins iD, Andrea Ng iD und 39 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01655 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Michael Sargent Binkley und 50 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHumansMaleAdultFemaleMiddle AgedRetrospective StudiesYoung AdultPrognosisProgression-Free SurvivalNeoplasm Staging

Autor:innen und Institutionen

  • Department of Radiation Oncology, Stanford School of Medicine, Stanford University, Stanford, CA.
  • Department of Oncology, St Jude Children's Research Hospital, Memphis, TN.
  • BC Cancer, Vancouver, Canada.
  • King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Oxford University, Oxford, United Kingdom.

ORCID-Profile: Michael Sargent Binkley, Jamie E Flerlage, Kerry J Savage, Raphael Steiner, Michael Dickinson, Ajay Major, David Hopkins, Andrea Ng, Carla Casulo, Jonathan Baron, Kenneth B Roberts, Jalila Al Kendi, Umberto Ricardi, Pallawi Torka, Lena Specht, Ravindu De Silva, Keir Pickard, Lindsay J Blazin, Christine M Smith, Jessica Brady, Maria Anatolevna Senchenko, Bradford S Hoppe, Stephanie Terezakis, Eliza A Hawkes, Nicole Wong Doo, Allison Barraclough, Chan Y Cheah, Matthew Ku, Nada Hamad, Michael Gilbertson, Tamara Marconi, Matthew J Maurer, Dennis A Eichenauer, Richard T Hoppe

Zitieren

APA

Binkley, M. S., Flerlage, J. E., Savage, K. J., Akhtar, S., Steiner, R., Zhang, X. Y., Dickinson, M., Prica, A., Major, A., Hendrickson, P. G., Hopkins, D., Ng, A., Casulo, C., Baron, J., Roberts, K. B., Al Kendi, J., Balogh, A., Ricardi, U., Torka, P., …, & GLOW Consortium (2024). International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01655

Vancouver

Binkley MS, Flerlage JE, Savage KJ, Akhtar S, Steiner R, Zhang XY, et al. International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01655

BibTeX
@article{Binkley2024,
  author = {Binkley, Michael Sargent and Flerlage, Jamie E and Savage, Kerry J and Akhtar, Saad and Steiner, Raphael and Zhang, Xiao-Yin and Dickinson, Michael and Prica, Anca and Major, Ajay and Hendrickson, Peter G and Hopkins, David and Ng, Andrea and Casulo, Carla and Baron, Jonathan and Roberts, Kenneth B and Al Kendi, Jalila and Balogh, Alex and Ricardi, Umberto and Torka, Pallawi and Specht, Lena and De Silva, Ravindu and Pickard, Keir and Blazin, Lindsay J and Henry, Michael and Smith, Christine M and Halperin, Daniel and Brady, Jessica and Brennan, Bernadette and Senchenko, Maria Anatolevna and Reeves, Marie and Hoppe, Bradford S and Terezakis, Stephanie and Talaulikar, Dipti and Picardi, Marco and Kirova, Youlia and Fergusson, Paige and Hawkes, Eliza A and Lee, Denise and Doo, Nicole Wong and Barraclough, Allison and Cheah, Chan Y and Ku, Matthew and Hamad, Nada and Mutsando, Howard and Gilbertson, Michael and Marconi, Tamara and Viiala, Nicholas and Maurer, Matthew J and Eichenauer, Dennis A and Hoppe, Richard T and GLOW Consortium, GLOW Consortium},
  title = {International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01655}
}
Kostenlos starten →